Targeted delivery of gemcitabine to lung cancer cells via a hyaluronic acid-based nanoplatform

Fengbo Yu; Jingdan Cao; Xingjun Fan; Junxia Gao; Guifang Liu; Chonghuan Lin; Ying Zhu; Q R Wang

doi:10.1039/d6ra02076c

January 1, 2026RSC AdvancesOpen Access

Targeted delivery of gemcitabine to lung cancer cells via a hyaluronic acid-based nanoplatform

View Full Paper

Ask AI

Bookmark

Share

Key Points

This research aims to improve lung cancer treatment through targeted delivery of gemcitabine using a nanoplatform.
Developed a CD44-targeted nanoplatform (GEM@HA-(HAP/PSI)) for drug delivery.
Employed a high drug-loading HAP core and HA–PSI shell for active targeting and pH-responsive release.
Conducted in vitro and in vivo evaluations of antitumor effects.
The nanoplatform demonstrated superior in vitro antitumor activity compared to conventional delivery methods.
In vivo studies showed significant tumor suppression, indicating effective targeting to lung cancer cells.
CD44-mediated endocytosis facilitated enhanced drug uptake and release.

Implication

Highlights improved tumor suppression in lung cancer using a targeted nanoplatform, suggesting effective treatment.

Abstract

A CD44-targeted nanoplatform (GEM@HA-(HAP/PSI)) with a high drug-loading HAP core and HA–PSI shell enables active targeting, pH-responsive release, CD44-mediated endocytosis, superior in vitro antitumor activity and in vivo tumor suppression.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Yu et al. (2026) studied this question.

synapsesocial.com/papers/6a095b8e7880e6d24efe161c https://doi.org/10.1039/d6ra02076c

View Full Paper

Ask AI

Bookmark

Share

Targeted delivery of gemcitabine to lung cancer cells via a hyaluronic acid-based nanoplatform

Key Points

Implication

Abstract

Discussion

Cite This Study

Targeted delivery of gemcitabine to lung cancer cells via a hyaluronic acid-based nanoplatform

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading